期刊文献+

巴洛沙星的研究进展 被引量:2

暂未订购
导出
摘要 巴洛沙星可通过抑制敏感菌DNA旋转酶的活性,从而抑制敏感菌DNA合成,导致敏感菌死亡。该药抗菌谱广,毒性低,尤其对耐氟喹诺酮类药物的菌株有较强的抗菌作用。
作者 陈静 汪晖
出处 《医药导报》 CAS 2006年第8期779-781,共3页 Herald of Medicine
  • 相关文献

参考文献12

  • 1Kojima K,Ito T,Munemura K,et al. In Vitro antibacterial activity of balofloxacin[ J]. Jpn J Chemother, 1995,43(S5):60 -76.
  • 2Ito T,Kojima K,Koizumi K,et al.Inhibitory activity on DNA gyrase and intracellular accumulation of quinolones: structure-activity relationship of Q-35 analogs[J]. Biol Pharm Bull,1994,17(7) :927- 930,
  • 3田中香お里,加藤直樹,加藤はる,等.。ユキ一ノロン系抗菌藥balofloxacinの嫌気性菌に对する抗菌力[J].日本化学療法学会雑誌,1995,43(S-5):27—33.
  • 4渡边邦友,上野一惠,和田光一,等.新キ一ノロbalofloxacinのヒト粪便内細阿菌叢に及ほす影響[J].日本化学療法学会雑誌,1995,43(S-5):160—167.
  • 5Nakagawa T,Ishigai M,Kato M,et al. Pharmacokinetics of the new fluoroquinolone balofloxacin in mice, rats, and dogs [ J ].Arzneimittelforschung,1995,45(6):719 -722.
  • 6Kamijo T, Haruta K, Asano T, et al. General pharmacology of balofloxacin, a new oral quinolone antibacterial agent ( 1 ): Effect on the central nervous system, autonomic nervous system and somatic nervous system[J]. Jpn Pharmacol Ther, 1995,23 (Suppl):121.
  • 7Ishizuka N, Kimura K, Matsuzawa M, et al. General pharmacology of balofloxacin, a new oral quinolone antibacterial agent (2):Effect on the cardiovascular system, smooth muscle, gastrointestinal,urinarysystem, blood and inflammation [ J ]. Jpn Pharmacol Ther,1995,23 ( Suppl. 6) : 155.
  • 8Sakamaki Y, Matsuzawa T, Matsushita T,et al.Single-dose oral toxicity study of balofloxacin ( Q-35 ) in mice, mrs and dogs [ J ]. Jpn Pharmacol Ther, 1995,23 ( Suppl 6 ):5.
  • 9Sakamaki Y, Matsuzawa T, Koizumi T, et al. 6-Month oral toxicity study of balofloxacin ( Q-35 ) [ J]. Jpn Pharmacol Ther, 1995,23( Suppl 6):35.
  • 10井上誠.Balofloxacinの安全性評偭新規キノロン系抗菌剤Balofloxacin(Q-35)の遺伝毒性[J].藥理と治療,1995,23(Suppl 6):1627—1635.

同被引文献16

  • 1糜志远,刘万忠.新氟喹诺酮类抗生素巴洛沙星研究进展[J].中国新药杂志,2005,14(9):1205-1210. 被引量:21
  • 2陈静,吴勇.巴洛沙星的体外抗菌作用研究[J].医药导报,2006,25(11):1126-1128. 被引量:4
  • 3[4]Nagano Hiroyukl.Novel quinolone-carboxylicacid derivatives:EP,34-2675[ P].1989-11-23.
  • 4[5]Shimizu Hirohito,FujimuraYasuo.Production of quinolonecarboxylic acid deriva-Tives:WO,9322308[ P].1992-04-28.
  • 5[6]Ochi K.Process for producing quinolonecarboxylic acid derivative.EP,0641782A1[ P].1992-07-15.
  • 6[7]Takagi N,Fubasami H,Matsukubo H.(6,7) subst-ituted-8-alkoxyl-cyclopropyl-1,4dihydro-4-oxo-3-quinoline-carboxylicacid-(03,04)-bis(acyloxy-0) borate and the salt thereof and the preparing method of the same:US,57117[ P].1992-10-20.
  • 7[8]Kohtaro Osakada,Takao Ikariya,Masahiko,et al.New chiral aminophosphines prepared from L-ornithine and catalytic asymme-tric hydrogenation using their rhodium (i) complexes[ J ].Chemistry Letters,1981,10(12):1691-1694.
  • 8Nakagwa A,Ishigai M,Kato M,et al.Pharmacokinetics of the new fluoroquinolone balofloxacin in mice,rats,and dogs[J].Arzneimittelforsch ung,1995,45(6):719-722.
  • 9Kojima K,Ito T,Munemura K,et al.In vitro antibacterial activity of balofloxacin[J].Jpn J Chemother,1995,43(5s):60-76.
  • 10Ito T,Kojima K,Koizumi K,et al.Inhibitory activity on DHA gyrase and intracellular aceumulatien of quinolones:structure-activity relationship of Q-35 analogs[J].Bil Pharm Bull,1994,17(7):927-930.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部